ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Long-term treatment with testosterone undecanoate injections in men with low T improves ED and reduces mortality
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 139192" data-attributes="member: 13851"><p><strong>Long-term treatment with testosterone undecanoate injections in men with hypogonadism improves ED and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality </strong></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Farid Saad, Monica Caliber, Gheorghe Doros, Karim Sultan Haider & Ahmad Haider </span></strong></p><p></p><p></p><p><strong>ABSTRACT </strong></p><p></p><p><span style="color: rgb(184, 49, 47)"><strong>Objective: </strong></span>The association between erectile dysfunction (ED), hypogonadism, cardiovascular disease, and type 2 diabetes is well documented, but long-term data are limited. The aim of this study is to investigate effects of long-term testosterone therapy (TTh) with testosterone undecanoate in men with hypogonadism and ED.</p><p></p><p><span style="color: rgb(184, 49, 47)"><strong>Patients and methods:</strong></span> Observational, prospective registry of 805 hypogonadal men with different degrees of ED, evaluated by the International Index of Erectile Function – Erectile Function Domain. Four hundred and twelve patients underwent TTh, 393 patients served as controls, with an observation period up to 12 years.</p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Results:</span></strong> TTh led to substantial and sustained reduction of ED; improvement in erectile function was significant for each successive year until year 9. This was accompanied by improvements in cardiometabolic risk factors and urinary function throughout the 12-year follow-up period. Benefits of TTh were stronger for patients with moderate/severe ED than for patients with no/ minor ED. Incidence of prostate cancer, major adverse cardiovascular events, and mortality were significantly lower in men on TTh compared with untreated men.</p><p></p><p><span style="color: rgb(184, 49, 47)"><strong>Conclusion:</strong></span> Long-term TTh for up to 12 years alleviates ED, improves cardiometabolic risk factors, and reduces prostate cancer. Patients must stay on TTh consistently for a long time to achieve maximum benefits of TTh.</p><p></p><p></p><p></p><p></p><p></p><p></p><p><strong>Conclusion </strong></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Long-term TTh with T undecanoate for up to 12 years significantly alleviates ED and markedly improves anthropometric obesity measures and metabolic risk factors. </span>The new finding in the present study is that <span style="color: rgb(184, 49, 47)">erectile function continues to significantly improve for 9 years during long-term continuous TTh.</span></strong></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">I</span></strong><span style="color: rgb(184, 49, 47)"><strong>mportantly, men who had been treated with T undecanoate had lower incidence of </strong></span><span style="color: rgb(0, 0, 0)"><strong>prostate cancer, major adverse cardiovascular events as well as mortality compared with untreated men.</strong></span> The present study underscores the importance for patients to stay on testosterone therapy consistently for a much longer time period than reported in randomized controlled studies in order to achieve maximum benefits of TTh in clinical practice.</p></blockquote><p></p>
[QUOTE="madman, post: 139192, member: 13851"] [B]Long-term treatment with testosterone undecanoate injections in men with hypogonadism improves ED and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality [/B] [B][COLOR=rgb(184, 49, 47)]Farid Saad, Monica Caliber, Gheorghe Doros, Karim Sultan Haider & Ahmad Haider [/COLOR][/B] [B]ABSTRACT [/B] [COLOR=rgb(184, 49, 47)][B]Objective: [/B][/COLOR]The association between erectile dysfunction (ED), hypogonadism, cardiovascular disease, and type 2 diabetes is well documented, but long-term data are limited. The aim of this study is to investigate effects of long-term testosterone therapy (TTh) with testosterone undecanoate in men with hypogonadism and ED. [COLOR=rgb(184, 49, 47)][B]Patients and methods:[/B][/COLOR] Observational, prospective registry of 805 hypogonadal men with different degrees of ED, evaluated by the International Index of Erectile Function – Erectile Function Domain. Four hundred and twelve patients underwent TTh, 393 patients served as controls, with an observation period up to 12 years. [B][COLOR=rgb(184, 49, 47)]Results:[/COLOR][/B] TTh led to substantial and sustained reduction of ED; improvement in erectile function was significant for each successive year until year 9. This was accompanied by improvements in cardiometabolic risk factors and urinary function throughout the 12-year follow-up period. Benefits of TTh were stronger for patients with moderate/severe ED than for patients with no/ minor ED. Incidence of prostate cancer, major adverse cardiovascular events, and mortality were significantly lower in men on TTh compared with untreated men. [COLOR=rgb(184, 49, 47)][B]Conclusion:[/B][/COLOR] Long-term TTh for up to 12 years alleviates ED, improves cardiometabolic risk factors, and reduces prostate cancer. Patients must stay on TTh consistently for a long time to achieve maximum benefits of TTh. [B]Conclusion [/B] [B][COLOR=rgb(184, 49, 47)]Long-term TTh with T undecanoate for up to 12 years significantly alleviates ED and markedly improves anthropometric obesity measures and metabolic risk factors. [/COLOR]The new finding in the present study is that [COLOR=rgb(184, 49, 47)]erectile function continues to significantly improve for 9 years during long-term continuous TTh.[/COLOR][/B] [B][COLOR=rgb(184, 49, 47)]I[/COLOR][/B][COLOR=rgb(184, 49, 47)][B]mportantly, men who had been treated with T undecanoate had lower incidence of [/B][/COLOR][COLOR=rgb(0, 0, 0)][B]prostate cancer, major adverse cardiovascular events as well as mortality compared with untreated men.[/B][/COLOR] The present study underscores the importance for patients to stay on testosterone therapy consistently for a much longer time period than reported in randomized controlled studies in order to achieve maximum benefits of TTh in clinical practice. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Long-term treatment with testosterone undecanoate injections in men with low T improves ED and reduces mortality
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top